Chairman and Former Chief Executive Office r · Kalaris Therapeutics, Inc. (KLRS)

David Hallal

A named executive officer of Kalaris Therapeutics in every fiscal year CompBrief holds from FY2019 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$16,797,713

Salary $219,000Stock awards $6,620,880

FY2020: $15,258,586

1st of 5 named executive officers at Kalaris Therapeutics by FY2021 total.

5 named officers on file for Kalaris Therapeutics, FY2021

David Hallal’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Kalaris Therapeutics’s whole pay program stands against its peers

  • Kalaris Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on KLRS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 6, 2022 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get David Hallal’s full pay file as a PDF — free

More than this page: up to 10 years of David’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

David Hallal compensation by year

Kalaris Therapeutics Summary Compensation Table · all 3 fiscal years held
In US dollars, as Kalaris Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020FY2021
Salary$550,000$566,500$219,000
Bonus$5,000$0$0
Stock awards$2,677,235$0$6,620,880
Option awards$0$14,277,568$9,781,229
Non-equity incentive$330,000$410,713$81,562
Pension and deferred compensation$0$0$0
All other$2,875$3,805$95,042
Total$3,565,110$15,258,586$16,797,713

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Kalaris Therapeutics, Inc. DEF 14A filed April 6, 2022, accession 0001193125-22-097515, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Kalaris Therapeutics, Inc. filed document, accession 0001193125-22-097515. Every figure is read from that document and cited to the page and table it appears in. Filed April 6, 2022.

$3.6M
$15.3M
$16.8M
FY19
FY20
FY21
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
RSU404,750$5,237,465—
RSU250,139$3,236,799—
RSU147,000$1,902,180—
Option756,938—$17.00
Option22,500—$21.51
Option273,000—$45.04

Per the Outstanding Equity Awards at Fiscal Year-End table in Kalaris Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

2 Form 4 lines since the FY2021 proxy (filed April 6, 2022)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-06-03Grant or award derivative—9,000$0.009,000
2025-04-10Grant or award derivative—18,000$0.0018,000

The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Kalaris Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
David Hallal · this pageChairman and Former Chief Executive Office r$16,797,713
Diana BrainardChief Executive Officer$15,136,121
Vikas SinhaPresident and Chief Financial Officer$6,622,996
Agustin MelianFormer Chief Medical Officer$5,830,095
Jeroen van BeekChief Commercial Officer$4,172,849

Board service

Kalaris Therapeutics board · FY2022–FY2025
Director compensation in US dollars, as Kalaris Therapeutics reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$140,000—$104,430$0$244,430
FY2024$200,000$27,027—$0$227,027
FY2023$200,000$147,000$0$0$347,000
FY2022$208,556—$93,029$45,819$347,404

Each year as the company reported it in Kalaris Therapeutics's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: Kalaris Therapeutics pays directors a $40,000 cash retainer. As stated in Kalaris Therapeutics's FY2025 proxy.

Committees

Compensation

The full Kalaris Therapeutics compensation record

free company brief

This page is one person within Kalaris Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Kalaris Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

David Hallal's compensation dossier · One-time report. No refunds.